semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Amputation Males or females between the ages of 18 and 65 Candidates for elective unilateral or bilateral lower extremity amputation at either the above knee or below knee level due to traumatic injury, congenital limb deformities or progressive arthritis Must demonstrate sufficiently sound health to undergo the operative procedure, including adequate cardiopulmonary stability to undergo general anesthesia (specifically, American Society of Anesthesiology Class I or II) Must have intact inherent wound healing capacity Must demonstrate adequate communication skills to convey the status of their sensorimotor recovery throughout the postoperative phase Must exhibit proper level of motivation to comply with postoperative follow up requirements Must be willing to also consent to protocol #1801183130 at Massachusetts Institute of Technology (approved by the Committee on the Use of Humans as Experimental Subjects) as some outcome measures will be assessed under this affiliated study  Patients beyond the stated age restrictions Those with severe illness rendering them unable to undergo the operative procedure safely (e.g., unresolved sepsis or cardiopulmonary instability manifest as documented coronary artery disease and/or chronic obstructive pulmonary disease) Patients with impairment in inherent wound healing pathways, such as those with primary connective tissue disorders or those on chronic steroid therapy Patients with extensive peripheral neuropathies (diabetic or otherwise) that would potentially inhibit appropriate reinnervation of the surgical constructs Active smokers; those patients willing to undergo tobacco cessation will need to be completely abstinent from tobacco use for at least 6 weeks preoperatively Patients who are unable to provide informed consent and those with a demonstrated history of poor compliance Pregnant women will not be considered due to the potential risks of general anesthesia. Patients will not be excluded from participation in the study on the grounds of minority status, religious status, race or gender. Non-English speaking patients will not be excluded from the study; interpreters will be made available to them for translation of both verbal interactions and written documents
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain, Mechanical Nonspecific LBP (LBP other than those excluded, see  below) any duration with pain pain primarily localized between T12 and gluteal folds age 18 years or older average pain intensity reported as moderate, or severe, or very severe on a five point Pain Intensity Short-form Scale over the past week is a Nepalese and is able to understand and speak Nepali fluently Participants with likely specific causes of LBP will be excluded using a triage procedure as suggested by Bardin and colleagues having history of prolonged use of corticosteroid history of malignancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Eating Behavior Body Weight Fibromyalgia Female subjects between the ages of 18-40 Subjects, who met the 2013 American College of Rheumatology (ACR) for Fibromyalgia  History of eating disorders such as anorexia nervosa, bulimia nevroza History of hypothyroidism or hyperthyroidism Pregnant or breast feeding History of central or peripheral nervous system disorders History of infectious, chronic inflammatory disease, malignant tumors Subjects with active psychiatric illness or who use psychiatric medication Uncooperative subject History of cardiac pathology such as heart failure, coronary artery disease History of diabetes, chronic renal insufficiency, chronic liver failure
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Primary Hypercholesterolemia Subjects who are 18 to 75 years of age, male or female using a highly effective birth control method or not of child-bearing potential, at Visit 1 (screening visit) LDL-C 130 to 189 mg/dL (inclusive) on a cholesterol lowering diet but no lipid modifying drug treatment for at least 6 weeks A qualifying LDL-C value must be obtained at the beginning and end of the placebo run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the value at Visit 2, higher or lower; the average of both qualifying values must be in the range of 130 to 189 mg/dL (inclusive) for in the study TG ≤ 350 mg/dL on a cholesterol lowering diet but no lipid modifying drug treatment for at least 6 weeks and TG levels must be ≤ 350 mg/dL at both Visit 2 and Visit 3 Signed written informed consent  Liver transaminases > 1.5 x upper limit of normal Homozygous Familial Hypercholesterolemia Subject who was diagnosed as diabetes with aged greater than 40 years old Subject who was diagnosed as diabetes with one of the following of cardiovascular risk factorss: Hypertention Bp ≥ 140/90mmHg,or smoking, or low HDL-C (1.04mmol/L), or BMI≥28kg/m2 Women who are pregnant or breast feeding Atherosclerotic cardiovascular disease including Arteriosclerotic heart disease, Acute coronary syndrome，Coronary artery bypass graft,Coronary angioplastyPeripheral arteriosclerosis,Cerebrovascular accident history of Severe Endiocrine disease (for example Thyroid function abnormal) History of a positive test for human immunodeficiency virus, hepatitis B or hepatitis C History of advanced cancer Arrhythmias need to be treated by medications
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-95.0,  Hemodialysis Complication all incident patients 18 years and older with CKD stage 5 started on hemodialysis  late-stage cancer patients and participants who are terminally ill defined as having an expected survival of less than 3 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-44.0,  Plasma Volume Micronutrients Menstrual Cycle Female to 44 years of age General good health (does not have a known, ongoing health condition/medical issue that requires regular monitoring by a doctor or regular visits to the hospital) BMI 18.5-24.9 kg/m2 Regular menstrual cycle (26-35 days) Non-smoker Non-pregnant If pregnant before, ≥12 months since last pregnancy  Known allergy to shellfish or iodine Blood pressure on the day of measurements is low or high (systolic blood pressure (SBP) <90 or ≥130 mmHg and/or diastolic blood pressure (DBP) <60 or ≥80 mmHg) Currently has low or high blood pressure (SBP <90 or ≥130 mmHg and/or DBP <60 or ≥80 mmHg), self-reported Current hypertension or previous hypertensive disorder in pregnancy (gestational hypertension or preeclampsia) Taking regular medication(s) (physician's prescribed medications for a health condition) Currently trying to conceive Currently breastfeeding Currently using hormonal birth control or used within last 3 months Used depot medroxyprogesterone acetate (DMPA) in the past 12 months Diagnosis of polycystic ovary syndrome
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hyperthyroidism Thyroidectomy PTH Immunochromatographic Primary hyperthyroidism Secondary hyperthyroidism Unilateral thyroidectomy Total thyroidectomy and bilateral central compartment dissection  age Older than 70 or younger than 18
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Labor Pain primiparous women with uncomplicated singleton pregnancies between 37 and 41 weeks gestation, cephalic, with cervical dilatation 3 to 5cm  multiparous with complicated pregnancies , multiple gestation
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Arthralgia Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy Male or female (aged ≥18 years old) Performance Status (PS) between 0 and 2 Expected life> 3 months Ability to answer a self-questionnaire Obtaining the non-opposition of patient participation  Pregnant or lactating woman Rapid evolution of neoplastic pathology Major cognitive disorders that do not allow filling of the self-questionnaire Impossibility to submit to medical monitoring for social, psychological or geographical reasons Patients under guardianship or curatorship
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Low Back Pain Female between 18 and 50 years of age with chronic nonspecific low back pain for more than three months  Serious spinal pathologies (fractures, tumors, and inflammatory pathologies such as ankylosing spondylitis) Nerve root compromise (disc herniation and spondylolisthesis with neurological compromise, spinal stenosis, and others) Fibromyalgia Corticosteroid treatment in the previous two weeks Antiinflammatory treatment in the previous 24 hours Contraindications to the use of Kinesio Taping (allergy or intolerance) Score of two or less on Visual Analogue Scale of the first day Pregnancy Previous Kinesio Tape therapy on lumbar
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Arthritis, Rheumatoid Diagnosed with RA Age of 20 years or over Disease considered have been stable for at least 3 months Able to understand and comply with the study treatment  Suffering from other terminal illnesses, severe dementia or another debilitating psychiatric disorder Living in a long-term care facility Participation in another research protocol
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ulcerative Colitis in Remission Ultrasound Relapse/Recurrence A confirmed diagnosis of ulcerative colitis Six-point Mayo score ≤ 1 Two consecutive faecal calprotectin tests <200 mg/kilogram Male or non-pregnant, non-nursing female ->18 years of age at Patients treated for minimum 1 year with first-line anti-tumor necrosis factor (TNF) treatment in sustained clinical remission during the last 3 months Subject capable of understanding and signing an informed consent form  Discontinuation of systemic 5-acetylsalicylic acid (ASA) or immunomodulatory therapy or other medication that could affect disease activity during the last 3 months prior to randomization Any treatment of systemic corticosteroids due to disease exacerbation during the last 3 months (i.e. patients being in steroid free clinical remission Patients on anti-TNF monotherapy with intolerance to both 5-ASA and immunomodulatory therapy Change in the anti-TNF treatment during the last 3 months due to disease related factors, not including dose/frequency adjustments due to drug concentration measurements Use of any second-line anti-TNF medication irrespective of reason for stopping first-line anti-TNF Previous failed attempts of anti-TNF discontinuation of more than 4 months' duration, with the exception of discontinuation due to pregnancy Detection of anti-TNF antibodies in moderate-high titers prior to randomization Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible Pregnancy Breastfeeding
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 21.0-39.0,  Hypovitaminosis D hypovitaminosis D (serum 25 OH D < 20 ng/ml)  Chronic disease causing Vitamin D deficiency like CKD, nephrotic syndrome, liver disease, hyperparathyroidism, history of skin graft, malabsorption, hyperthyroidism, drugs like anticonvulsants, glucocorticoids, HAART Current pregnancy Lactose intolerance Previously treated with bolus Vitamin D supplementation within previous three months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 15.0-60.0,  Treatment of Arthritis Patients suffering from Arthritis  Patients with Hypertension, Cardiovascular disorders and Kidney disorders were excluded
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Prolonged Labor women with spontaneous labour in the first stage of labour cervical dilatation in between 4-7 centimeters singleton pregnancy gestation of at least 37 completed weeks cephalic presentations no additional complications  women with ante partum hemorrhage breech presentation multiple pregnancy premature labour (before 37 weeks) Eclampsia elective caesarean section induced labour
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Parathyroid Adenoma Hypercalcemia above 18 years old participants that suffer from primary hyperparathyroidism with an indication for parathyroidectomy  Chronic renal failure kidney transplant participant MEN (multiple endocrine neoplasia) syndrome pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant Patient received de novo renal transplant Patient treated with MyOra® according to the attending physician's judgment (either post-transplant or induction) Patient provided written informed consent  Hypersensitivity to mycophenolate mofetil, mycophenolic acid (MPA) or any of the constituents of MyOra®
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease Stage 3 Adult (age 18+) English-speaking CKD patients stage 3 (eGFR = 30-70 mL/min) who are scheduled for a clinic visit will be eligible for participation. 1. Up to 60 will receive the QPS and all data collection activities 2. Up to 10 will be audio recorded only 2. Nephrologists (or Nurse Practitioners or Physician Assistants) seeing CKD patients in routine clinic visits will be eligible for participation at Hines, VA  CKD patients who are non-English speaking, blind, hard of hearing or deaf, unable to read, and/or who are cognitively impaired will not be eligible for participation
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Chronic Pain years of age or older having a CMMSE score over or equal to 15 having chronic pain or a widespread pain condition such as fibromyalgia for at least 3 months be willing to participate in the research, with informed consent signed by their guardian or carer  being allergic to essential oils refusal to give consent being over-sensitive to tactile stimulation having a history of kidney and liver disease no history of an epileptic seizure
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 15.0-45.0,  Anemia, Iron Deficiency Age 15-45 years old at intake Confirmed intrauterine pregnancy by 1st trimester ultrasound  Antepartum iron supplementation, other than prenatal vitamins Placental abruption or hemorrhage Initial visit >20 weeks gestation Diagnosis of sickle cell disease or thalassemia Diagnosed with anemia at initial prenatal visit Diagnosis of autoimmune issues that could effect iron levels
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Phosphorus and Calcium Disorders patients with diagnosis of primary hyperparathyroidism HIV-infected patients with reduced phosphorus but normal calcium subjects with normal Calcium-Phosphorus metabolism  for both cases and controls will be age younger than 18 or older than 90 years severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min) hyperparathyroidism secondary to Vitamin D deficiency active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc) any type of cancer malnutrition severe obesity (BMI > 40 kg/m2) a history of gastrointestinal malabsorption sarcoidosis